Blog
RSS FeedPosted by Michael Wonder on 21 Oct 2023
Rezolute receives Priority Medicines (PRIME) eligibility from EMA for enhanced regulatory support of RZ358 in congenital hyperinsulinism
17 October 2023 - PRIME eligibility granted based on key positive data from the Phase 2B (RIZE) study and current ...
Posted by Michael Wonder on 19 Jan 2023
The battle over European drug pricing
19 January 2023 - UK and EU must balance health cost control with plans to grow life sciences. ...
Posted by Michael Wonder on 02 Aug 2021
Pfizer, Moderna raise prices of COVID-19 coronavirus vaccines for European Union
1 August 2021 - What’s the best way to get more people vaccinated against COVID-19 to try to end the ...
Posted by Michael Wonder on 16 Mar 2021
EU regulators team up with U.S. and UK on pharmaceutical mergers
16 March 2021 - EU antitrust enforcers have teamed up with their U.S. and British counterparts to share expertise on ...
Posted by Michael Wonder on 10 Feb 2021
Drug maker will slash prices on cancer medicines to end price gouging probe in Europe
10 February 2021 - After months of deliberation, the European Commission has accepted an offer from Aspen Pharma to reduce ...
Posted by Michael Wonder on 14 Jul 2020
Aspen offers to cut cancer drug prices, may avoid EU antitrust fine
14 July 2020 - Aspen has offered to cut prices by an average of 73% for six off-patent cancer drugs, ...
Posted by Michael Wonder on 06 Nov 2019
One shot drug to end Sicilian curse comes at $1.8 million cost
5 November 2019 - A new targeted gene therapy shows the promise and pitfalls of medical advances. ...
Posted by Michael Wonder on 15 Jun 2019
Bluebird Bio CEO defends $1.8 million price for gene therapy — ‘It’s really thinking about it differently’
14 June 2019 - He says the one-time treatment is a game changer for patients, giving them a “lifelong benefit” while ...
Posted by Michael Wonder on 23 Nov 2018
Novartis's pricing might be tested with costly eye therapy
23 November 2018 - Novartis’s price-setting muscle is about to be tested after it won European Union approval for a blindness-fighting ...
Posted by Michael Wonder on 04 Nov 2018
Are rumours of AbbVie's Humira price cuts what they seem?
2 November 2018 - In an effort to combat competition from biosimilar adalimumab products in Europe as patents covering the ...
Posted by Michael Wonder on 01 Nov 2018
AbbVie offers a ‘huge’ discount on Humira to fend off European rivals
1 November 2018 - In hopes of fending off biosimilar competition for its franchise drug, AbbVie has apparently won the ...
Posted by Michael Wonder on 23 Jan 2018
Competition in pharmaceuticals: more product- than price-oriented?
23 January 2018 - Competition is a subject always open to debate in health care, and pharmaceuticals are no exception, with ...
Posted by Michael Wonder on 09 Oct 2017
Is the NHS being held to ransom by big pharma?
7 October 2017 - Late last year Britain’s competition watchdog slapped a record £90m worth of fines on US drugs ...
Posted by Michael Wonder on 19 Oct 2016
Aspen fined over huge price hikes
19 October 2016 - Company found to have overcharged for older-generation cancer drugs in Italy ...
Posted by Michael Wonder on 11 May 2016
Drug regulation and pricing — can regulators influence affordability?
12 May 2016 - Although drug regulators aren’t supposed to be concerned with pricing, they’ve been drawn into an acrimonious debate ...